Several other acquired HER2 mutations were also found in the circulating tumor DNA (ctDNA) of patients following progression on neratinib, including R678Q, V697L, T862A, and I767M; more than one acquired HER2 mutation was found in the same patient. The gene discussed is ERBB2; the disease is neoplasm.